Eli Lilly and Company announced today that the European Commission has approved a new indication for FORSTEO(R) (teriparatide [rDNA origin] injection) for the treatment of osteoporosis associated with sustained, systemic glucocorticoid therapy in women and men at increased risk for fracture. Teriparatide stimulates new bone formation by increasing the number and action of bone-building cells called osteoblasts.
Friday, April 4, 2008
Lilly's Forsteo Approved by European Commission
Eli Lilly and Company announced today that the European Commission has approved a new indication for FORSTEO(R) (teriparatide [rDNA origin] injection) for the treatment of osteoporosis associated with sustained, systemic glucocorticoid therapy in women and men at increased risk for fracture. Teriparatide stimulates new bone formation by increasing the number and action of bone-building cells called osteoblasts.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment